financetom
Business
financetom
/
Business
/
Cascades Prices Offering of US$400 Million Senior Notes Due 2030
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cascades Prices Offering of US$400 Million Senior Notes Due 2030
May 29, 2025 4:20 AM

07:12 AM EDT, 05/29/2025 (MT Newswires) -- Cascades (CAS.TO), a player in eco-friendly recovery, packaging, and hygiene products, overnight Wednesday priced its private placement of US$400 million of 6.750% Senior Notes due July 15, 2030.

The company said the notes, the sale of which is expected to close on June 11, will be issued at 100% of their principal amount. Along with the company, Cascades USA, a U.S. indirect wholly owned unit of CAS, will be a co-issuer in respect of the notes.

Proceeds from the offering will be used to redeem all of its outstanding US$206 million of 5.125% Senior Notes due Jan. 15, 2026, to repay a portion of the borrowings outstanding under its revolving credit facility and to pay related transaction fees and expenses.

Shares of the company closed up 0.2% to $8.76 on Wednesday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lazard Reports Increase in AUM for October
Lazard Reports Increase in AUM for October
Nov 12, 2025
07:13 AM EST, 11/12/2025 (MT Newswires) -- Lazard ( LAZ ) said Wednesday it had $267.78 billion in assets under management as of Oct. 31, up from $264.54 billion at the end of September. The month's AUM reflected $6.9 billion in market appreciation, $1.4 billion in net outflows, and $2.2 billion in foreign exchange depreciation. Lazard ( LAZ ) said...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Unicycive Therapeutics Q3 net loss widens to $6 mln
Unicycive Therapeutics Q3 net loss widens to $6 mln
Nov 12, 2025
Overview * Unicycive reports Q3 net loss of $6.0 mln, up from $4.1 mln year-over-year * Company plans to resubmit NDA for OLC by year-end after FDA discussions * Unicycive ends Q3 with $42.7 mln cash, runway into 2027 Outlook * Unicycive plans to resubmit NDA for OLC by year-end * Company expects cash runway into 2027 * Unicycive anticipates...
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Copyright 2023-2026 - www.financetom.com All Rights Reserved